SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim President and Chief Executive Officer, succeeding Michael W.
SAN DIEGO --(BUSINESS WIRE)--Feb. 10, 2022-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, has appointed Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer. With more than 30 years of healthcare experience,
SAN DIEGO --(BUSINESS WIRE)--Jan. 21, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.
SAN DIEGO --(BUSINESS WIRE)--Jan. 4, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held
Spotlight Presentation at SABCS showed that in 38% of patients the HER2 status of the metastatic cancer differed from the primary tumor, offering new information to aid treatment decisions SAN DIEGO --(BUSINESS WIRE)--Dec. 9, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular
Targeted Lung Panel Now Available with Physician’s Order at Quest’s 2,200 Patient Service Centers Nationwide SECAUCUS, N.J. AND SAN DIEGO – December 1, 2021 – Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics
Biocept continues to expand and perform COVID-19 testing services using Thermo Fisher Scientific platform SAN DIEGO --(BUSINESS WIRE)--Nov. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, now offers a single test that can detect
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced the presentation of a multi-institutional case
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Third paragraph, sixth sentence of release should read: CNSide detected CSF tumor cells in all eleven measurements taken, compared to six of eleven using cytology.
Revenues for the third quarter of $17.5 million , up 165% over prior-year quarter, driven by increased RT-PCR COVID-19 testing, resulting in profitability; cash balance of $27.7 million at quarter-end Robust CNSide™ sequential-quarter volume growth; continued customer base expansion Data generated